Back to Search
Start Over
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE
- Source :
- Journal of Bone Oncology, Journal of Bone Oncology, Vol 26, Iss, Pp 100341-(2021)
- Publication Year :
- 2020
-
Abstract
- Highlights • Bone remodeling is disrupted in metastatic disease, affecting > 70% of mCRPC men. • In metastatic disease, abnormal levels of specific BTMs are released. • We prospectively measured four BTMs markers in chemotherapy-naïve mCRPC men on AAP therapy. • AAP seems to act on the microenvironment of metastatic but not of normal bone. • This action likely contributes to the antitumoral activity of AAP.<br />Background Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration-resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this prospective ancillary analysis of the Italian real-world study ABITUDE, four markers were measured during abiraterone acetate plus prednisone (AAP) treatment in chemotherapy-naïve mCRPC men failing androgen-deprivation therapy. Methods Patients were enrolled if a blood sample was obtained before the first administration of abiraterone (baseline); ad-hoc blood samples were withdrawn during routine tests after 3, 6, and 12 months. A centralized lab measured bone alkaline phosphatase (BALP, osteoblast activity marker), type-I collagen-C-telopeptide (CTX-1, bone resorption marker), parathyroid hormone (PTH) and vitamin D (vitD). At each time point, intra-patient variations vs baseline were compared by the signed-rank test (statistical significance: P-value
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system
Abiraterone acetate
Bone alkaline phosphatase
Bone targeting therapy
Bone turnover biomarkers
C-terminal telopeptide
mCRPC
Urology
Parathyroid hormone
lcsh:RC254-282
Settore MED/06
Bone resorption
Bone remodeling
03 medical and health sciences
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Settore MED/36
Prednisone
medicine
Vitamin D and neurology
business.industry
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
030104 developmental biology
Oncology
chemistry
030220 oncology & carcinogenesis
lcsh:RC925-935
business
medicine.drug
Research Article
Subjects
Details
- ISSN :
- 22121366
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Journal of bone oncology
- Accession number :
- edsair.doi.dedup.....1a8ec0a57936f350d221b062fd34b9c6